Loading...
8 items
2026-05-15
Soken Chemical & Engineering Co., Ltd., Annual General Meeting, Jun 24, 2026.
2026-05-09
Soken Chemical & Engineering Co., Ltd. announced that they will report Q1, 2027 results on Aug 05, 2026
2026-05-09
Soken Chemical & Engineering Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026
2026-04-27
Gel Coat Biomaterials, Inc. announced that it has received ¥200 million in a round of funding on April 27, 2026. The transaction include participation from new investors, WUV1 Fund, fund managed by WASEDA University Ventures, Inc. and Soken Chemical & Engineering Co., Ltd. The company issued convertible preferred shares in the transaction. The shares were issued through a third-party allocation.
2026-02-23
Soken Chemical & Engineering Co., Ltd. expected to report Fiscal Year 2026 results on May 15, 2026. This event was calculated by S&P Global (Created on February 23, 2026).
2025-11-15
Soken Chemical & Engineering Co., Ltd. expected to report First-Half, 2026 results on November 21, 2025. This event was calculated by S&P Global (Created on November 15, 2025).
2025-11-06
Soken Chemical & Engineering Co., Ltd., ¥ 75.0, Cash Dividend, Mar-30-2026
2025-10-14
PITTAN Co., Ltd. announced that it has received ¥160,000,000 in a round of funding on October 10, 2025. The transaction included participation from new investors, Chushin Venture Capital Co., Ltd., Soken Chemical & Engineering Co., Ltd., Lion Corporation, returning investors, Quantum Leap Ventures, and Kyoto Capital & Partners Co., Ltd. The company has issued convertible preferred stock in the transaction. The company has raised the funding through a third-party allotment of new shares.
2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 | 2024Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | 49,071 | 47,967 | 47,300 | 46,053 | 47,355 | 47,633 | 45,510 | 46,394 | 43,929 | 41,318 |
Pretax Income Excl.Unusual Items | 6,701 | 6,238 | 5,868 | 5,585 | 5,826 | 6,339 | 5,828 | 5,763 | 5,028 | 3,908 |
Total Assets | 59,263 | 58,708 | 55,147 | 53,021 | 52,638 | 54,114 | 52,890 | 55,210 | 52,929 | 50,582 |
Total Liabilities | 17,040 | 17,216 | 15,485 | 15,106 | 15,563 | 16,112 | 16,462 | 18,730 | 18,579 | 17,848 |
Cash & Cash Equivalents | 5,017 | 6,860 | 5,859 | 6,187 | 6,601 | 8,413 | 7,256 | 7,937 | 6,583 | 7,576 |
Total Common Equity | 42,223 | 41,492 | 39,662 | 37,915 | 37,075 | 38,002 | 36,428 | 36,480 | 34,350 | 32,734 |
Book Value Per Share (BVPS) | 2,544.3 | 2,500.25 | 2,389.97 | 2,284.69 | 2,236.12 | 2,292.04 | 2,197.08 | 2,200.22 | 2,073.88 | 1,976.31 |
Net Change in Cash | 1,446 | 1,250 | 2,837 | 3,401 | 3,063 | |||||
Capital Expenditure | -2,798 | -1,440 | -1,490 | -1,797 | -2,263 |
On August 05, 2026, Soken Chemical & Engineering shared its financial results for the second quarter of 2026, with revenues of 12.48B yen and net income of 1.38B yen, indicating a growth of 9.7% in revenue, coupled with a substantial increase of about 43.7% in EPS relative to the corresponding quarter last year.
In addition, the EBITDA margin improved from 17.85% in the corresponding quarter last year to 18.77%. and it trades at 16.5x times current year's earnings, which is higher than the sector average (P/E 10.9x).
